Cargando…
Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response
BACKGROUND: Treatment options for advanced cervical cancer are limited and patients experiencing recurrence after first-line cisplatin-based chemotherapy and bevacizumab have a poor prognosis. A recent phase II study in advanced cervical cancer has demonstrated a disease control rate of 68.4% with t...
Autores principales: | Baettig, Florence, Vlajnic, Tatjana, Vetter, Marcus, Glatz, Katharina, Hench, Jürgen, Frank, Stephan, Bihl, Michel, Lopez, Roberto, Dobbie, Michael, Heinzelmann-Schwarz, Viola, Montavon, Céline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824124/ https://www.ncbi.nlm.nih.gov/pubmed/31672171 http://dx.doi.org/10.1186/s40425-019-0742-6 |
Ejemplares similares
-
L1CAM is not a reliable predictor for lymph node metastases in endometrial cancer, but L1CAM positive patients benefit from radiotherapy
por: Zeiter, Deborah, et al.
Publicado: (2021) -
Zoon vulvitis
por: Damiani, Leandro, et al.
Publicado: (2017) -
Vulvitis Infantalis
Publicado: (1880) -
Plasma cell vulvitis
por: Bharatia, Pravin R., et al.
Publicado: (2015) -
On the Various Forms of Vulvitis
por: Simpson,
Publicado: (1860)